$QBTS · D-Wave Quantum Inc.
D-Wave Quantum filed an 8-K disclosing two developments: a non-binding MOU with LG CNS to advance quantum optimization adoption in South Korea and international markets, and news that customer Shionogi won the NEDO Challenge QOL category for quantum-assisted drug discovery research. The LG CNS collaboration aims to move annealing quantum computing applications from proof of concept into production across manufacturing, telecom, finance, and retail. The Shionogi research demonstrated 97% chemical validity for quantum-assisted molecular generation versus 73% for classical models.
- D-Wave and LG CNS signed a non-binding MOU to deploy annealing quantum computing for enterprise optimization in manufacturing, telecom, finance, and retail.
- Shionogi won first place in the NEDO Challenge QOL category for quantum-assisted drug discovery research using D-Wave technology.
- The Shionogi study showed 97% of quantum-assisted molecular representations were chemically valid vs. 73% for the classical model.
- The NEDO prize awards ¥40 million to support Shionogi's continued quantum drug discovery research.
- The LG CNS collaboration targets moving quantum applications from proof of concept into production with joint go-to-market efforts.
Extended-hours trading shows QBTS at $12.30, up 1.40% from the regular-session close of $12.13, suggesting modest positive reception to the dual announcements. Markets were closed at filing; the after-hours move indicates initial investor optimism around the LG CNS partnership and Shionogi validation.
D-Wave lands a strategic Asian enterprise partner and a peer-reviewed validation milestone on the same day, strengthening both its commercial pipeline and scientific credibility.
Quantum computing partnerships with major Asian enterprise IT firms remain rare; LG CNS brings established client relationships across South Korea's manufacturing and public sectors, potentially opening a new commercial geography for D-Wave's annealing technology.
The LG CNS agreement is a non-binding MOU with no guarantee of reaching definitive agreements or generating revenue. Forward-looking statements carry standard caveats about actual results differing materially.